NicOx's HCT 1026 Shows Positive Clinical Dermatology Results in Prolonged Contact Urticaria

Apr 18, 2001, 01:00 ET from NicOx SA

    SOPHIA ANTIPOLIS, France, April 18 /PRNewswire/ -- NicOx SA
 (Nouveau Marche: NICOX) announced positive human clinical results with
 HCT 1026, its nitric oxide-releasing derivative of the non-steroidal
 anti-inflammatory (NSAID) compound, flurbiprofen, in drug induced prolonged
 contact urticaria.  Contact urticaria is a temporary localized rash induced by
 contact with a topical chemical irritant.
     This Phase I/II dermatology clinical study on HCT 1026 has been
 successfully completed on 16 healthy subjects and has evaluated two
 concentrations of HCT 1026 ointment (0.3% and 1%) versus placebo (vehicle) and
 a reference NSAID (niflumic acid 3% ointment).  The ointments were applied in
 duplicate and left for 3-1/2 hours, after which the irritant was applied at
 each test site, as well as 48 hours later.
     HCT 1026 1% ointment showed an anti-inflammatory activity significantly
 more potent than the reference NSAID 4 hours after application thus confirming
 the results of a first phase I/II study in acute contact urticaria (press
 release July 3, 2000).  A dose effect response with HCT 1026 0.3% and
 1% ointments was also seen 4 hours after application.  48 hours after
 application, the HCT 1026 ointment was the only compound that showed a lasting
 anti-inflammatory activity.  The local and general safety of HCT 1026 was
 excellent.
     Mr. Michele Garufi, Chairman and CEO of NicOx commented:  "These further
 encouraging clinical results confirm the potential of HCT 1026 for topical
 application.  HCT 1026, as well as the nitric oxide steroid derivative NCX
 1022, at present in Phase I, may represent the platform for a broad strategic
 alliance with a partner with an expertise in dermatology and interested in the
 exploitation of nitric oxide-releasing drugs topical application."
 
     NicOx is an emerging pharmaceutical company harnessing recently-discovered
 properties of nitric oxide to design and develop safer and more effective
 drugs.  NicOx is targeting several major therapeutic markets including pain
 and inflammation, cardiovascular diseases, urinary incontinence, asthma,
 inflammatory bowel diseases, dermatological disorders, liver diseases,
 Alzheimer's disease and cancer.  Based in Sophia-Antipolis, France, NicOx is a
 Public Company listed on the Nouveau Marche of the Paris Stock Exchange.
 
 

SOURCE NicOx SA
    SOPHIA ANTIPOLIS, France, April 18 /PRNewswire/ -- NicOx SA
 (Nouveau Marche: NICOX) announced positive human clinical results with
 HCT 1026, its nitric oxide-releasing derivative of the non-steroidal
 anti-inflammatory (NSAID) compound, flurbiprofen, in drug induced prolonged
 contact urticaria.  Contact urticaria is a temporary localized rash induced by
 contact with a topical chemical irritant.
     This Phase I/II dermatology clinical study on HCT 1026 has been
 successfully completed on 16 healthy subjects and has evaluated two
 concentrations of HCT 1026 ointment (0.3% and 1%) versus placebo (vehicle) and
 a reference NSAID (niflumic acid 3% ointment).  The ointments were applied in
 duplicate and left for 3-1/2 hours, after which the irritant was applied at
 each test site, as well as 48 hours later.
     HCT 1026 1% ointment showed an anti-inflammatory activity significantly
 more potent than the reference NSAID 4 hours after application thus confirming
 the results of a first phase I/II study in acute contact urticaria (press
 release July 3, 2000).  A dose effect response with HCT 1026 0.3% and
 1% ointments was also seen 4 hours after application.  48 hours after
 application, the HCT 1026 ointment was the only compound that showed a lasting
 anti-inflammatory activity.  The local and general safety of HCT 1026 was
 excellent.
     Mr. Michele Garufi, Chairman and CEO of NicOx commented:  "These further
 encouraging clinical results confirm the potential of HCT 1026 for topical
 application.  HCT 1026, as well as the nitric oxide steroid derivative NCX
 1022, at present in Phase I, may represent the platform for a broad strategic
 alliance with a partner with an expertise in dermatology and interested in the
 exploitation of nitric oxide-releasing drugs topical application."
 
     NicOx is an emerging pharmaceutical company harnessing recently-discovered
 properties of nitric oxide to design and develop safer and more effective
 drugs.  NicOx is targeting several major therapeutic markets including pain
 and inflammation, cardiovascular diseases, urinary incontinence, asthma,
 inflammatory bowel diseases, dermatological disorders, liver diseases,
 Alzheimer's disease and cancer.  Based in Sophia-Antipolis, France, NicOx is a
 Public Company listed on the Nouveau Marche of the Paris Stock Exchange.
 
 SOURCE  NicOx SA